Neurofibromatosis type II therapy (Oddifact)

N/A

Report date: 2025/05/16 16:52:16

Base Information

Drug NameNeurofibromatosis type II therapy (Oddifact)
Drug Alias NameBevacizumab (Oddifact)贝伐珠单抗 (Oddifact)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsNeurofibromatosis 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOddifact SAS
China Registration ClassN/A

Develop Information

Active CompaniesOddifact SAS
Inactive CompaniesN/A
Active IndicationsNeurofibromatosis 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A